Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma

Benjamin M Ellingson, Kunal Patel, Chencai Wang, Catalina Raymond, Andrew Brenner, John F de Groot, Nicholas A Butowski, Leor Zach, Jian L Campian, Jacob Schlossman, Shan Rizvi, Yael C Cohen, Noa Lowenton-Spier, Tamar Rachmilewitz Minei, Shifra Fain Shmueli, Patrick Y Wen, Timothy F Cloughesy

Open source

DOI: 10.1093/noajnl/vdab082
Published: 2021-01-01
Container: Neuro-Oncology Advances
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/noajnl/vdab082,
  title = {Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma},
  author = {Benjamin M Ellingson and Kunal Patel and Chencai Wang and Catalina Raymond and Andrew Brenner and John F de Groot and Nicholas A Butowski and Leor Zach and Jian L Campian and Jacob Schlossman and Shan Rizvi and Yael C Cohen and Noa Lowenton-Spier and Tamar Rachmilewitz Minei and Shifra Fain Shmueli and Patrick Y Wen and Timothy F Cloughesy},
  year = {2021},
  journal = {Neuro-Oncology Advances},
  doi = {10.1093/noajnl/vdab082},
  url = {https://doi.org/10.1093/noajnl/vdab082}
}

RIS

TY  - JOUR
TI  - Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma
AU  - Benjamin M Ellingson
AU  - Kunal Patel
AU  - Chencai Wang
AU  - Catalina Raymond
AU  - Andrew Brenner
AU  - John F de Groot
AU  - Nicholas A Butowski
AU  - Leor Zach
AU  - Jian L Campian
AU  - Jacob Schlossman
AU  - Shan Rizvi
AU  - Yael C Cohen
AU  - Noa Lowenton-Spier
AU  - Tamar Rachmilewitz Minei
AU  - Shifra Fain Shmueli
AU  - Patrick Y Wen
AU  - Timothy F Cloughesy
PY  - 2021
JO  - Neuro-Oncology Advances
DO  - 10.1093/noajnl/vdab082
UR  - https://doi.org/10.1093/noajnl/vdab082
ER  -

APA

Ellingson, B. M., Patel, K., Wang, C., Raymond, C., Brenner, A., Groot, J. F. D., Butowski, N. A., Zach, L., Campian, J. L., Schlossman, J., Rizvi, S., Cohen, Y. C., Lowenton-Spier, N., Minei, T. R., Shmueli, S. F., Wen, P. Y., & Cloughesy, T. F. (2021). Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdab082

Source records

crossref · retrieved 2026-09-26T00:11:46.532Z